samedan logo
 
 
 
spacer
home > ebr > spring 2002 > pharmacogenetics and the development of anticancer agents
PUBLICATIONS
European Biopharmaceutical Review

Pharmacogenetics and the Development of Anticancer Agents

The observation that individuals respond differently to the same drug is centuries old, yet only recently has the biological basis for such variation begun to be unravelled. In the field of pharmacogenetics, detailed biological understanding of the pathways by which drugs act and are metabolised, guides high throughput DNA sequencing efforts to reveal variations within genes critical to therapeutic response. Such variance data is used to associate responsiveness to a drug with specific genetic variations, which can then serve as predictive markers to guide drug usage. This article summarises progress in identifying genetic markers that predict the toxicity and efficacy of chemotherapeutic drugs. Several types of markers have been associated with response to a variety of anticancer agents, including DNA polymorphisms, loss of heterozygosity, and RNA expression patterns within tumours. Some genetic features of cancer that provide the basis for these markers are outlined briefly, examples of each type of marker are provided, and the utility of pharmacogenetics throughout the drug development process is discussed.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ann E. Ferentz, Senior Scientist and Manager of Scientific Communications at Variagenics, Inc

Ann Ferentz obtained her BS from Yale University and her PhD in Chemistry from Harvard University. Her subsequent research at Harvard Medical School and the Massachusetts Institute of Technology focused on structural biology and cellular responses to DNA damage.
She is currently a Senior Scientist and Manager of Scientific Communications at Variagenics, a pharmacogenomics company in Cambridge, Massachusetts.

spacer
Ann E. Ferentz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Albumedix announces recombinant human albumin supply partnership with FUJIFILM Wako Pure Chemical Corporation for the Japanese, Chinese and Hong Kong markets

Nottingham, UK – 29th March 2021 – Life Science Newswire – Albumedix Ltd. (‘Albumedix’), an enabler of advanced therapies and world leader in recombinant human albumin (rHA), announced today that they have entered into a distribution agreement with established and well recognized reagent supplier FUJIFILM Wako Pure Chemical Corporation (FUJIFILM Wako) in Japan and China including Hong Kong.
More info >>

White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>

 
Industry Events

MedTech Integrates 2021

22 June 2021, VIRTUAL CONFERENCE

Inspired by the success of the inaugural MedTech Integrates in last October, Life Science Integrates is delighted to announce the second Medtech Integrates conference. This one-day gathering of technology, diagnostics, devices and therapeutics organisations, as well as clinicians and regulators, provides a platform to discuss the major challenges impacting the MedTech sector.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement